Viking Therapeutics VKTX Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's other income, net (note 6)?
- Viking Therapeutics (VKTX) reported other income, net (note 6) of $5.8M in Q1 2026.
- How has Viking Therapeutics's other income, net (note 6) changed year-over-year?
- Viking Therapeutics's other income, net (note 6) decreased by 41.1% year-over-year, from $9.84M to $5.8M.
- What is the long-term trend for Viking Therapeutics's other income, net (note 6)?
- Over 4 years (2021 to 2025), Viking Therapeutics's other income, net (note 6) has grown at a 164.2% compound annual growth rate (CAGR), from $692K to $33.7M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.